UY35765A - FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO. - Google Patents

FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.

Info

Publication number
UY35765A
UY35765A UY0001035765A UY35765A UY35765A UY 35765 A UY35765 A UY 35765A UY 0001035765 A UY0001035765 A UY 0001035765A UY 35765 A UY35765 A UY 35765A UY 35765 A UY35765 A UY 35765A
Authority
UY
Uruguay
Prior art keywords
hmpv
need
adjuvant
liofilized
lives
Prior art date
Application number
UY0001035765A
Other languages
English (en)
Inventor
Bueno Ramírez Susan Marcela
Kalergis Parra Alexis Mikes
Palavecino Beaumont Christian
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Publication of UY35765A publication Critical patent/UY35765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe una formulación inmunogénica para ser utilizada en mamíferos contra Metapneumovirus humano (hMPV) consistente en un liofilizado de 1x109 ufc/ml de BCG recombinantes que expresa la proteína viral P de hMPV (de los genogrupos A1, A2, B1 y B2). La vacuna esta derivada del producto completo o parcial del gen P de hMPV pudiendo ser utilizadas, estabilizadas y administradas en solución sin la necesidad de adyuvantes. La formulación está estabilizada por liofilización (rango de conservación entre 4°C y 8°C), para ser posteriormente reconstituida en una solución salina sin adyuvante previo a su uso.
UY0001035765A 2013-10-01 2014-10-01 FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO. UY35765A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013002829A CL2013002829A1 (es) 2013-10-01 2013-10-01 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.

Publications (1)

Publication Number Publication Date
UY35765A true UY35765A (es) 2015-04-30

Family

ID=52778317

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035765A UY35765A (es) 2013-10-01 2014-10-01 FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.

Country Status (17)

Country Link
US (1) US9999663B2 (es)
EP (1) EP3054013B1 (es)
KR (1) KR101822836B1 (es)
CN (1) CN105745323B (es)
AR (1) AR097881A1 (es)
BR (1) BR112016006989B1 (es)
CA (1) CA2925369C (es)
CL (1) CL2013002829A1 (es)
DE (1) DE112014004530T5 (es)
ES (1) ES2853355T3 (es)
GB (1) GB2532699B (es)
MX (1) MX2016003783A (es)
PE (1) PE20160536A1 (es)
RU (1) RU2665848C2 (es)
UY (1) UY35765A (es)
WO (1) WO2015049633A1 (es)
ZA (1) ZA201602148B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
CL2019003847A1 (es) * 2019-12-26 2021-08-06 Univ Pontificia Catolica Chile Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
WO2022133622A1 (es) * 2020-12-23 2022-06-30 Pontificia Universidad Catolica De Chile Formulación inmunogénica que contiene una o más cepas bcg modificadas que expresan una proteína de sars-cov-2, útil para prevenir, tratar o atenuar el desarrollo de covid-19.
CN114748615A (zh) * 2022-04-29 2022-07-15 成都安永鼎业生物技术有限公司 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途
CN114767842A (zh) * 2022-04-29 2022-07-22 成都安永鼎业生物技术有限公司 一种重组卡介苗的冻干制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040002853A (ko) 2001-01-19 2004-01-07 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
EP1485468A4 (en) * 2002-02-21 2007-01-03 Medimmune Vaccines Inc RECOMBINANT PARAIN FLUENZAVIRUS EXPRESSION SYSTEMS AND VACCINES WITH ANTIGENS FROM METAPNEUMOVIRUS STEM-RELATED HETEROLOGISTS
EP1622574A4 (en) 2003-04-25 2006-10-18 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
US9034343B2 (en) 2005-01-12 2015-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated human parainfluenza virus, methods and uses thereof
EP2152863B1 (en) 2007-05-08 2012-09-19 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human parainfluenza viruses having separated p and c genes
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
GB0809881D0 (en) * 2008-05-30 2008-07-09 Genomica Sau Method for detecting respiratory viral agents in a test sample

Also Published As

Publication number Publication date
BR112016006989A2 (pt) 2017-09-19
GB2532699A (en) 2016-05-25
CA2925369A1 (en) 2015-04-09
MX2016003783A (es) 2017-01-20
AR097881A1 (es) 2016-04-20
RU2665848C2 (ru) 2018-09-04
ES2853355T3 (es) 2021-09-15
CN105745323B (zh) 2020-09-04
KR20160058185A (ko) 2016-05-24
EP3054013A1 (en) 2016-08-10
ZA201602148B (en) 2017-06-28
CN105745323A (zh) 2016-07-06
KR101822836B1 (ko) 2018-01-29
PE20160536A1 (es) 2016-06-05
WO2015049633A1 (es) 2015-04-09
CL2013002829A1 (es) 2014-04-04
US20160220662A1 (en) 2016-08-04
EP3054013B1 (en) 2020-11-11
GB2532699B (en) 2020-05-13
US9999663B2 (en) 2018-06-19
EP3054013A4 (en) 2016-08-31
GB201605054D0 (en) 2016-05-11
RU2016111978A (ru) 2017-11-10
BR112016006989B1 (pt) 2023-10-17
DE112014004530T5 (de) 2016-10-06
CA2925369C (en) 2020-09-22

Similar Documents

Publication Publication Date Title
UY35765A (es) FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.
PH12018502403A1 (en) Hiv vaccine formulation
NZ707328A (en) Virus-containing formulation and use thereof
MX2023003875A (es) Formulacion de una vacuna peptidica.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
JP2015524462A5 (es)
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
NZ714163A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
MX386142B (es) COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
EP4056198A3 (en) Outer membrane vesicles
MX2016007726A (es) Inmunoterapia de cancer mediante el suministro de antigenos mhc clase ii usando un replicon de vlp.
CL2024001738A1 (es) Vacunas peptídicas
MX2019003961A (es) Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
MX2016012447A (es) Formulaciones de factor ix liofilizadas.
PH12018500458A1 (en) Vlp stabilized vaccine compositions
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
WO2014165829A3 (en) Nanoparticle formulations
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
MX2017004378A (es) Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.
CL2016003199A1 (es) Células madre derivadas de sangre menstrual para el tratamiento del carcinoma pancreático humano

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230918